Letermovir

• CAT Number: I005468
• CAS Number: 917389-32-3
• Molecular Formula: C29H28F4N4O4
• Molecular Weight: 572.60
• Purity: 98%
• Synonyms: 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
• Target: CMV
• Solubility: 10 mM in DMSO
• Appearance: Solid Powder
• Storage: Store at -20°C
• Analysis method: HPLC
• IC50: 5.1±1.2 nM (EC50, HCMV-AD169 strain, CPE reduction assay)
• InChI: InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
• InChIKey: FWYSMLBETOMXAG-QHCPKHFHSA-N
• SMILES: COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O

Letermovir（Cat No.:I005468）is a potent antiviral agent primarily used for the prevention of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients. It acts as a selective inhibitor of the CMV terminase complex, which is crucial for viral DNA cleavage and packaging. By targeting this enzyme, Letermovir prevents the replication of CMV, reducing the risk of CMV reactivation. Its well-established safety profile and efficacy make it an essential option in post-transplant immunocompromised patients, helping mitigate the complications associated with CMV infection.

Reference

1: Erb-Zohar K, Kropeit D, Scheuenpflug J, Stobernack HP, Hulskotte E, van Schanke A, Zimmermann H, Rübsamen-Schaeff H. Intravenous Hydroxypropyl β-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial. Clin Transl Sci. 2017 Nov;10(6):487-495. doi: 10.1111/cts.12483. Epub 2017 Jul 4. PubMed PMID: 28675594.
2: Bowman LJ, Melaragno JI, Brennan DC. Letermovir for the management of cytomegalovirus infection. Expert Opin Investig Drugs. 2017 Feb;26(2):235-241. doi: 10.1080/13543784.2017.1274733. Epub 2016 Dec 28. Review. PubMed PMID: 27998189.
3: Wildum S, Zimmermann H, Lischka P. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59(6):3140-8. doi: 10.1128/AAC.00114-15. Epub 2015 Mar 16. PubMed PMID: 25779572; PubMed Central PMCID: PMC4432118.
4: Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610-3. doi: 10.1128/AAC.01794-13. Epub 2013 Nov 4. PubMed PMID: 24189264; PubMed Central PMCID: PMC3910730.
5: Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13. PubMed PMID: 21752907; PubMed Central PMCID: PMC3187482.